Azelnidipine is a useful medication for the treatment of heart failure preserved ejection fraction

References

• Catterall WA, Striessnig J. Receptor sites for Ca2+ channel antagonists. Trends Pharmacol Sci 1992;13:256–262.
   PubMed Web of Science ®Google Scholar
• Kimura Y, Hirooka Y, Sagara Y, Sunagawa K. Long-acting calcium channel blocker, azelnidipine, increases endothelial nitric oxide synthase in the brain and inhibits sympathetic nerve activity. Clin Exp Hypertens 2007;29:13–21.
   PubMed Web of Science ®Google Scholar
• Konno S, Hirooka Y, Araki S, et al. Azelnidipine decreases sympathetic nerve activity via antioxdant effect in the rostral ventrolateral medulla of stroke-prone spontaneously hypertensive rats. J Cardiovasc Phaemacol 2008;52:555–560.
   PubMed Web of Science ®Google Scholar
• Tanaka M, Sekioka R, Nishimura T, et al. Effects of cilnidipine on sympathetic nerve activity and cardiorenal function in hypertensive patients with type 2 diabetes mellitus: association with BNP and aldosterone levels. Diabetes Res Clin Pract 2014;106:504–510.
   PubMed Web of Science ®Google Scholar
• Fujii S, Kameyama K, Hosono M, et al. Effect of cilnidipine, a novel dihydropyridine Ca++ channel antagonist, on N-type Ca++ channel in rat dorsal root ganglion neurons. J Pharmacol Exp Ther 1997;280:1184–1191.
   PubMed Web of Science ®Google Scholar
• Marui A, Nishiwaki N, Komiya T, et al. Comparison of 5-year outcomes after coronary artery bypass grafting in heart failure patients with versus without preserved left ventricular ejection fraction (from the CREDO-Kyoto CABG Registry Cohort-2). Am J Cardiol 2015;116:580–586.
   PubMed Web of Science ®Google Scholar
• Shimamoto K, Ando K, Fujita T, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014). Hypertens Res 2014;37:253–390.
   PubMed Web of Science ®Google Scholar
• Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009;53:982–992.
   PubMed Web of Science ®Google Scholar
• Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18;499–502.
   Google Scholar
• Teichholz LE, Kreulen T, Herman MV, Gorlin R. Problems in echocardiographic volume determinations: echocardiographic-angiographic correlations in the presence or absence of asynergy. Am J Cardiol 1976;37:7–11.
   PubMed Web of Science ®Google Scholar
• Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989;2:358–367.
   PubMed Web of Science ®Google Scholar
• Hisatake S, Nanjo S, Fujimoto S, et al. Comparative analysis of the therapeutic effects of long-acting and short-acting loop diuretics in the treatment of chronic heart failure using (123)I-metaiodobenzylguanidine scintigraphy. Eur J Heart Fail 2011;13:892–898.
   PubMed Web of Science ®Google Scholar
• Abe H, Mita T, Yamamoto R, et al. Comparison of effects of cilnidipine and azelnidipine on blood pressure, heart rate and albuminuria in type 2 diabetics with hypertension: A pilot study. J Diabetes Invest 2013;4:202–205.
   PubMed Web of Science ®Google Scholar
• Tsuchihashi-Makaya M, Kinugawa S, Yokoshiki H, et al. Beta-blocker use at discharge in patients hospitalized for heart failure is associated with improved survival. Circ J 2010;74:1364–1371.
   PubMed Web of Science ®Google Scholar
• Ahn SA, Jong P, Yusuf S, et al. Early versus delayed enalapril in patients with left ventricular systolic dysfunction: impact on morbidity and mortality 15 years after the SOLVD trial. J Am Coll Cardiol 2006;47:1904–1905.
   PubMed Web of Science ®Google Scholar
• Solomon SD, Wang D, Finn P, et al. Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation 2004;110:2180–83.
   PubMed Web of Science ®Google Scholar
• Kinouchi K, Ichihara A, Bokuda K, et al. Differential effects in cardiovascular markers between high-dose angiotensin II receptor blocker monotherapy and combination therapy of ARB with calcium channel blocker in hypertension (DEAR Trial). Int J Hypertens 2011;284823. doi: 10.4061/2011/284823
   PubMedGoogle Scholar
• Fukao K, Shimada K, Hiki M, et al. Effects of calcium channel blockers on glucose tolerance, inflammatory state, and circulating progenitor cells in non-diabetic patients with essential hypertension: a comparative study between azelnidipine and amlodipine on glucose tolerance and endothelial function–a crossover trial (AGENT). Cardiovasc Diabetol 2011;10:79. doi: 10.1186/1475-2840-10-79.
   PubMed Web of Science ®Google Scholar
• Takami T, Saito Y. Azelnidipine plus olmesartan versus amlodipine plus olmesartan on arterial stiffness and cardiac function in hypertensive patients: a randomized trial. Drug Des Devel Ther 2013;7:175–183.
   PubMed Web of Science ®Google Scholar
• Pathapati RM, Rajashekar ST, Buchineni M, et al. An open label parallel group study to assess the effects of amlodipine and cilnidipine on pulse wave velocity and augmentation pressures in mild to moderate essential hypertensive patients. J Clin Diagn Res 2015;9:FC13–16.
   PubMedGoogle Scholar
• Miranda SM, Moscavitch SD, Carestiato LR, et al. Cardiac I123-MIBG correlates better than ejection fraction with symptoms severity in systolic heart failure. Arq Bras Cardiol 2013;101:4–8.
   PubMed Web of Science ®Google Scholar
• Narula J, Gerson M, Thomas GS, et al. 123I-MIBG imaging for prediction of mortality and potentially fatal events in heart failure: the ADMIRE-HFX study. J Nucl Med 2015;56:1011–8.
   PubMed Web of Science ®Google Scholar
• Kuwabara Y, Tamaki N, Nakata T, et al. Determination of the survival rate in patients with congestive heart failure stratified by 123I-MIBG imaging: a meta-analysis from the studies performed in Japan. Ann Nucl Med 2011;25:101–107.
   PubMed Web of Science ®Google Scholar
• Kinbara T, Hayano T, Otani N, et al. Iodine-123 metaiodobenzylguanidine imaging can predict future cardiac events in Japanese patients with Parkinson’s disease. Ann Nucl Med 2013;27:123–131.
   PubMed Web of Science ®Google Scholar
• Lymperopoulos A1, Rengo G, Koch WJ. Adrenergic nervous system in heart failure: pathophysiology and therapy. Circ Res 2013;113:739–753.
   PubMed Web of Science ®Google Scholar